Harvard Bioscience (HBIO) Long-Term Deferred Tax (2010 - 2019)

Harvard Bioscience (HBIO) has 10 years of Long-Term Deferred Tax data on file, last reported at $210000.0 in Q2 2019.

• Quarterly Long-Term Deferred Tax rose 18.64% year-over-year to $210000.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $210000.0 (up 18.64% YoY) and the FY2017 annual result came in at $182000.0, down 84.27% from the prior year.
• Long-Term Deferred Tax climbed to $210000.0 in Q2 2019 per HBIO's latest filing, from $208000.0 in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $11.0 million in Q3 2015 and bottomed at -$5.0 million in Q4 2015.
• The 5-year median for Long-Term Deferred Tax is $1.0 million (2016), against an average of $2.2 million.
• The widest annual swing landed in 2015, when Long-Term Deferred Tax plunged 145.08%; it then soared 123.21% in 2016.
• Tracing HBIO's Long-Term Deferred Tax over 5 years: stood at -$5.0 million in 2015, then soared by 123.21% to $1.2 million in 2016, then slumped by 84.27% to $182000.0 in 2017, then slipped by 1.65% to $179000.0 in 2018, then gained by 17.32% to $210000.0 in 2019.
• Per Business Quant, the three latest HBIO Long-Term Deferred Tax figures stand at $210000.0 (Q2 2019), $208000.0 (Q1 2019), and $179000.0 (Q3 2018).

Peer Comparison